Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Vermont Tech Scene.
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 31, 2025
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal …
Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
GlobeNewswire
·
May 31, 2025
New York City, NY, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction In the crowded world of online trading platforms, separating legitimate services from elaborate scams can be a daunting task. Trade 350 App has emerged as one of the buzziest names in 2025, …
Starscope: Does Starscope Monocular Really Work for Stargazing & Hiking? Read Full Starscope Monocular Telescope Consumer Report!
GlobeNewswire
·
May 31, 2025
San Diego, CA, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction: Why the Starscope Monocular Is Gaining Popularity in 2025 Whether you're a nature lover, hiker, hunter, or stargazer, having the right optical gear can make or break your outdoor experience. In …
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
GlobeNewswire
·
May 31, 2025
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a UK-based cloud mining provider regulated by the Financial Conduct Authority (FCA), has announced a major expansion of its services. This strategic move comes amid a surge in global …
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
GlobeNewswire
·
May 31, 2025
Image by PAIRMiner STUTTGART, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- As Bitcoin prices rise past key resistance levels, investor interest in digital assets is once again on the upswing. PAIRMiner, a cloud-based cryptocurrency mining platform, is helping …
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
GlobeNewswire
·
May 31, 2025
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to …
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
GlobeNewswire
·
May 31, 2025
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
GlobeNewswire
·
May 31, 2025
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median …
Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
GlobeNewswire
·
May 31, 2025
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1. L’analyse post-hoc de l’étude NAPOLI 3 a permis de déterminer …
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
GlobeNewswire
·
May 31, 2025
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years …
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
GlobeNewswire
·
May 31, 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, …
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
GlobeNewswire
·
May 31, 2025
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple cancers with elevated incidence and mortality in a high-risk population Data …
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
GlobeNewswire
·
May 31, 2025
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37 weeks through the data cutoff, …
Online Crypto Casinos: All iGaming Reveals the Top Sites for Crypto Gamblers in 2025
GlobeNewswire
·
May 31, 2025
Jersey City, NJ, May 31, 2025 (GLOBE NEWSWIRE) -- - These days, the internet is flooded with crypto casinos all claiming to offer the best games, biggest bonuses, and fastest payouts. But finding a truly reputable crypto casino isn’t about luck- it’s …
Free Psychic Medium Readings | Chat with Real Mediums Online – Special 2025 Announcement
GlobeNewswire
·
May 31, 2025
San Francisco, CA, May 31, 2025 (GLOBE NEWSWIRE) -- - In today's digital age, connecting with a psychic medium is easier and more accessible than ever. Whether you're seeking comfort after a loss, clarity on life’s deeper questions, or simply curious about …
PAIRMiner Launches $150 Cloud Mining Incentive as Institutional Bitcoin Holdings Reach Historic Levels
GlobeNewswire
·
May 31, 2025
Amid a surge in institutional Bitcoin investments, PAIRMiner introduces a free cloud mining offer to make crypto access easier for everyday users. Image by PAIRMiner LOS ANGELES, May 31, 2025 (GLOBE NEWSWIRE) -- Cloud mining platform PAIRMiner today …
Snail Inc. 旗下独立品牌 Wandering Wizard 与拉丁美洲工作室 Seven Leaf Clover 达成发行合作，加速全球市场布局
GlobeNewswire
·
May 31, 2025
加利福尼亚州卡尔弗城, May 31, 2025 (GLOBE NEWSWIRE) -- 全球领先的互动数字娱乐领域独立开发商与发行商 Snail, Inc. (Nasdaq: SNAL，以下简称 “Snail Games” 或 “公司”) 宣布，其独立游戏发行品牌 Wandering Wizard 已与阿根廷开发商 Seven Leaf Clover 达成发行合作协议，获得高强度第一人称单人射击游戏 (FPS) Rebel Engine 的发行权。 Rebel Engine 预计将于 2025 年登陆 …
Snail Inc. 旗下獨立品牌 Wandering Wizard 與拉丁美洲工作室 Seven Leaf Clover 建立發行合作夥伴關係，擴大在全球市場的影響力
GlobeNewswire
·
May 31, 2025
加利福尼亞州卡爾弗城, May 31, 2025 (GLOBE NEWSWIRE) -- 全球領先的互動數碼娛樂獨立開發商及發行商 Snail, Inc. (Nasdaq: SNAL)（「Snail Games」或「公司」）宣布其獨立發行品牌 Wandering Wizard，與來自阿根廷的開發商 Seven Leaf Clover 建立發行合作夥伴關係，以獲取極具影響力、單人第一人稱射擊（「FPS」）遊戲 《Rebel Engine》 的發行權利。 遊戲預計將於 2025 年在 PC …
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
GlobeNewswire
·
May 31, 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, …
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS…
GlobeNewswire
·
May 31, 2025
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no …